Every year, our scientists and patient advisory group identify the studies and topics creating the most impact for people living with arthritis.
Uncover Our Focus for 2026Ongoing and completed studies across our full research portfolio, from prevention and treatment to care and health systems.
Explore Our ResearchMeet the scientists, clinicians, trainees, and patient advisory board members, driving discoveries
Meet Our TeamPeople living with arthritis guide our research priorities, shape study design, and ensure our work reflects real life.
Support Arthritis Research Canada with your time and skills. Whether you want to help at an event or host your own, there is a place for you here.
Living with arthritis? Explore open studies looking for participants and help shape the future of arthritis care.
Your experience with arthritis matters. Sharing it helps others feel less alone and brings the human reality of arthritis into everything we do.
Scientific Study Title:
Start Date:
End Date:
Research Category
Life-changing arthritis research is only possible with your help!
Reason For Research
Early and targeted treatment methods for rheumatoid arthritis (RA) can greatly improve patient outcomes. The Arthritis Alliance of Canada (AAC) highlights the importance of a continuum of RA care, from early diagnosis to ongoing treatment. The AAC developed a method to test the success of care models. It focuses on access to care and early treatment, using a set of quality measures. This study aimed to assess the effectiveness of RA care in two Canadian provinces, British Columbia (BC) and Alberta by looking at four system-level quality measures.
Execution of Research
Two research studies were done. One explored RA care in Alberta and one explored RA care in BC. In both provinces, researchers identified people diagnosed with RA using provincial health administrative data. The study periods looked at different years. The BC data focused on patients from 1997 to 2009 and followed up until 2014. The Alberta data included patients from 2012/13 to 2015/16. The quality of care measures were:
1) how long patients waited to see a rheumatologist,
2) how many patients had yearly follow-up appointments,
3) how many patients were taking medications known to slow down the disease (called disease-modifying antirheumatic drugs or DMARDs), and
4) how quickly patients started on DMARD therapy after being diagnosed.
Timeliness and Frequency of Seeing Rheumatologists: For both provinces, the percentage increased for newly diagnosed RA patients seeing a rheumatologist within a year. However, rates for annual follow-up with rheumatologists dropped in BC and varied in Alberta.
DMARD Therapy: In BC, the use of DMARDs was less than ideal across the total population but higher among patients under rheumatologist care. Alberta had a consistently low yearly rate of dispensing DMARDs. There were slight improvements in the median time for how quickly patients began DMARD therapy but failure to meet the 14-day mark for a large number of patients.
Gaps in Care: Both studies showed gaps in RA care, including barriers to seeing rheumatologists and getting DMARD therapy. Despite some improvements, care in both provinces falls short of national standards. This shows a need for quality improvement efforts.
This study consists of 4 sub-projects dedicated to achieving our overall goals. Click below for more information about each sub-project: